AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25307711 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 5 ml/kg of Ringer's acetate intravenously for over 15 min
Number of subjects: 30
Study 25308138 — intervention group
Group type: EXPERIMENTAL
Intervention: h-FABP above 6 μg/L
Number of subjects: 132
Study 25308138 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP > 100 pg/mL
Number of subjects: 132
Study 25308138 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI-Ultra > 0.05 μg/L
Number of subjects: 132
Study 25308138 — intervention group
Group type: EXPERIMENTAL
Intervention: PESI low class I or II
Number of subjects: 132
Study 25308138 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of h-FABP with PESI
Number of subjects: 132
Study 25308138 — intervention group
Group type: EXPERIMENTAL
Intervention: h-FABP
Number of subjects: 132
Study 25308138 — intervention group
Group type: EXPERIMENTAL
Intervention: PESI
Number of subjects: 132
Study 25308138 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 132
Study 25308138 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI-Ultra
Number of subjects: 132
Study 25308921 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-C3
Number of subjects: 194
Study 25308921 — intervention group
Group type: COMPARATOR
Intervention: C3M
Number of subjects: 194
Study 25308921 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Pro-C3
Number of subjects: 194
Study 25309090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP) tablets, 4 tablets with 250 mL of water every 15 min, three times on the day of the procedure.
Number of subjects: 30
Study 25310119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor Mother program
Number of subjects: 480
Study 25310119 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care, informal peer support
Number of subjects: 480
Study 25310303 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell-depleted haploidentical SCT (HHCT)
Number of subjects: 28
Study 25311774 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoperineal excision (APE)
Number of subjects: 108
Study 25311774 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative information regarding sexual dysfunction
Number of subjects: 108
Study 25311774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual activity
Number of subjects: 108
Study 25311774 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts about sex
Number of subjects: 108
Study 25311774 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with sexual function
Number of subjects: 108
Study 25311835 — intervention group
Group type: EXPERIMENTAL
Intervention: Later bedtime
Number of subjects: 22
Study 25311835 — intervention group
Group type: EXPERIMENTAL
Intervention: Later wake time
Number of subjects: 22
Study 25311835 — intervention group
Group type: EXPERIMENTAL
Intervention: Later midpoint of sleep
Number of subjects: 22
Study 25312446 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic monotherapy
Number of subjects: 0
Study 25312446 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic polytherapy
Number of subjects: 0
Study 25312446 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch therapy
Number of subjects: 0
Study 25312446 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on therapy
Number of subjects: 0
Study 25312446 — intervention group
Group type: EXPERIMENTAL
Intervention: Total disease-related cost per patient per annum
Number of subjects: 0
Study 25312446 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalisations
Number of subjects: 0
Study 25312446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home stays
Number of subjects: 0
Study 25312589 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (quitters)
Number of subjects: 81
Study 25313095 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg every 2 weeks (with dose adjustments for weight)
Number of subjects: 181
Study 25313914 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg recombinant-human chorionic gonadotropin
Number of subjects: 36
Study 25313914 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal women)
Number of subjects: 36
Study 25313914 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS women with normal 17-OHP responses
Number of subjects: 36
Study 25314069 — intervention group
Group type: EXPERIMENTAL
Intervention: α-tocopherol (50 mg/day)
Number of subjects: 29105
Study 25314069 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene (20 mg/day)
Number of subjects: 29105
Study 25314069 — intervention group
Group type: EXPERIMENTAL
Intervention: Both α-tocopherol and β-carotene
Number of subjects: 29105
Study 25314069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29105
Study 25314291 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-carriers (n=20)
Number of subjects: 40
Study 25314291 — intervention group
Group type: COMPARATOR
Intervention: CC-carriers (n=20)
Number of subjects: 40
Study 25314641 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg once daily plus carboplatin/paclitaxel
Number of subjects: 18
Study 25314641 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin/paclitaxel
Number of subjects: 18
Study 25315074 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y ibritumomab tiuxetan (Zevalin)
Number of subjects: 16
Study 25315258 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily
Number of subjects: 60
Study 25315502 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated patients (two-year weight loss = 16%)
Number of subjects: 500
Study 25315502 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically managed patients (two-year weight loss = 3%)
Number of subjects: 500
Study 25315502 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 500
Study 25315502 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 500
Study 25315502 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 500
Study 25315670 — intervention group
Group type: EXPERIMENTAL
Intervention: Naked oat combined with a structured dietary intervention
Number of subjects: 0
Study 25315670 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25316260 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 76304
Study 25316260 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 76304
Study 25316260 — intervention group
Group type: COMPARATOR
Intervention: Never smokers with passive smoking exposure
Number of subjects: 76304
Study 25316260 — intervention group
Group type: COMPARATOR
Intervention: Never smokers with adult home passive smoking exposure ≥30 years
Number of subjects: 76304
Study 25316347 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training for 12 weeks
Number of subjects: 31
Study 25316347 — intervention group
Group type: COMPARATOR
Intervention: Non-peripheral artery disease controls
Number of subjects: 31
Study 25316810 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD(-) cases at 12 months
Number of subjects: 415
Study 25316810 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD(-) cases at 24 months
Number of subjects: 415
Study 25316810 — intervention group
Group type: EXPERIMENTAL
Intervention: CR/PCR(-) cases
Number of subjects: 415
Study 25316810 — intervention group
Group type: EXPERIMENTAL
Intervention: PR/PCR(-) cases
Number of subjects: 415
Study 25317092 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 143
Study 25317092 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics and anthropometrics
Number of subjects: 143
Study 25317092 — intervention group
Group type: EXPERIMENTAL
Intervention: Day of the week and school break
Number of subjects: 143
Study 25317365 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 336
Study 25317365 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice daily
Number of subjects: 336
Study 25317365 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (both dosages)
Number of subjects: 336
Study 25317759 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient antimicrobial stewardship intervention
Number of subjects: 0
Study 25317759 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25317870 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor-modified T cells (CTL019)
Number of subjects: 30
Study 25318437 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg IV on Days 1, 8, 15, and 22 of a 28 day cycle and Bevacizumab 10 mg/kg IV on Days 1 and 15 of the cycle
Number of subjects: 28
Study 25318437 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus and Bevacizumab
Number of subjects: 28
Study 25319501 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-CAR T cells (1×10^6 CAR-transduced T cells per kg)
Number of subjects: 21
Study 25319501 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-CAR T cells
Number of subjects: 21
Study 25320340 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg/once daily) with prednisolone (5 mg/twice daily)
Number of subjects: 48
Study 25320355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus (10-40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week)
Number of subjects: 87
Study 25320355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus and dalotuzumab combination
Number of subjects: 87
Study 25320535 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART (66 Gy/30 F to PTV66 and 54 Gy/30 F to PTV54)
Number of subjects: 10
Study 25320535 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART
Number of subjects: 10
Study 25320633 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc and Raltegravir
Number of subjects: 22
Study 25320633 — intervention group
Group type: COMPARATOR
Intervention: Truvada® plus Kaletra® (control)
Number of subjects: 22
Study 25322359 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen fecal microbiota transplantation (FMT) capsules, 15 capsules administered on 2 consecutive days.
Number of subjects: 20
Study 25322531 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHG) in 70% alcohol
Number of subjects: 0
Study 25322531 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine
Number of subjects: 0
Study 25323055 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 363
Study 25323055 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 363
Study 25323230 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilic inflammation assessment in COPD patients
Number of subjects: 0
Study 25323247 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation by oncologist
Number of subjects: 140
Study 25323247 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 140
Study 25323247 — intervention group
Group type: COMPARATOR
Intervention: Performance status ⩽2
Number of subjects: 140
Study 25323247 — intervention group
Group type: COMPARATOR
Intervention: Nonprogressive malignancy
Number of subjects: 140
Study 25323247 — intervention group
Group type: COMPARATOR
Intervention: No explicit refusal of ICU admission
Number of subjects: 140
Study 25323247 — intervention group
Group type: COMPARATOR
Intervention: Initial ward other than lung cancer unit
Number of subjects: 140
Study 25323247 — intervention group
Group type: COMPARATOR
Intervention: Available medical ICU bed
Number of subjects: 140
Study 25323764 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH) therapy at a mean dose of 0.053 mg/kg/day over 3 years
Number of subjects: 19
Study 25323764 — intervention group
Group type: COMPARATOR
Intervention: historical cohort of untreated HCH children
Number of subjects: 19
Study 25324042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 100
Study 25324042 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 100
Study 25324973 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 ng aviscumine twice weekly by subcutaneous injection until progression
Number of subjects: 32
Study 25325296 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention services package including condom and lubricant choices, risk-reduction counseling, couples HIV testing and counseling, pre-exposure prophylaxis (PrEP), non-occupational post-exposure prophylaxis.
Number of subjects: 200
Study 25325296 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for health care providers to facilitate clinically and culturally competent care for MSM.
Number of subjects: 200
Study 25325480 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal breathing events defined by an apnea-hypopnea index (AHI) > 15
Number of subjects: 559
Study 25325480 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal breathing events defined by an apnea-hypopnea index (AHI) > 30
Number of subjects: 559
Study 25325480 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypoxemia defined as cumulative peripheral oxygen saturation (SpO2) < 90% or minimal SpO2
Number of subjects: 559
Study 25325684 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE) combined with endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
Number of subjects: 31
Study 25326006 — intervention group
Group type: EXPERIMENTAL
Intervention: First hospitalization for cardiovascular (CV) reasons
Number of subjects: 7599
Study 25326006 — intervention group
Group type: EXPERIMENTAL
Intervention: First hospitalization for non-cardiovascular (non-CV) reasons
Number of subjects: 7599
Study 25326006 — intervention group
Group type: COMPARATOR
Intervention: Not hospitalized
Number of subjects: 7599
Study 25326006 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day survivors of CV hospitalization
Number of subjects: 7599
Study 25326006 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day survivors of non-CV hospitalization
Number of subjects: 7599
Study 25326543 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 54
Study 25327505 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (20 mg/kg)
Number of subjects: 60
Study 25327505 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (25 mg/kg)
Number of subjects: 60
Study 25328681 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSTVAC immunotherapy
Number of subjects: 100
Study 25328711 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 6mg oral for 3 months
Number of subjects: 54
Study 25328711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 25329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313
Study 25329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313
Study 25329038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study 25329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (elevated SBP ≥140 mm Hg)
Number of subjects: 2313
Study 25329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg (elevated SBP ≥140 mm Hg)
Number of subjects: 2313
Study 25329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (elevated DBP ≥90 mm Hg)
Number of subjects: 2313
Study 25329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg (elevated DBP ≥90 mm Hg)
Number of subjects: 2313
Study 25329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (elevated DBP)
Number of subjects: 2313
Study 25329038 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg (elevated DBP)
Number of subjects: 2313
Study 25329562 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid 25 mg daily for 2 weeks
Number of subjects: 28
Study 25329562 — intervention group
Group type: COMPARATOR
Intervention: Control group (bile acid sequestrants discontinued)
Number of subjects: 28
Study 25329821 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1200 mg as carbonate)
Number of subjects: 1675
Study 25329821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1675
Study 25330000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 dietary pattern (least healthy)
Number of subjects: 45
Study 25330000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3 dietary pattern (healthiest)
Number of subjects: 45
Study 25330000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 dietary pattern (intermediate)
Number of subjects: 45
Study 25330000 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier dietary pattern
Number of subjects: 45
Study 25330463 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg QD sc for 12 weeks
Number of subjects: 36
Study 25330984 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectra Optia apheresis system (SO) for red blood cell exchange (RBCX) procedures
Number of subjects: 72
Study 25330984 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectra Optia apheresis system (SO) for achieving desired final hematocrit (Hct)
Number of subjects: 72
Study 25330984 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectra Optia apheresis system (SO) regarding safety
Number of subjects: 72
Study 25331113 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m² plus liposomal doxorubicin 20 mg/m² (R-Dox) every 3 weeks
Number of subjects: 17
Study 25331535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional exhaled nitric oxide (FeNO)
Number of subjects: 131
Study 25331535 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune globulin E (IgE)
Number of subjects: 131
Study 25331535 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood eosinophils
Number of subjects: 131
Study 25331535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 131
Study 25331616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m2, intravenous, twice a week for 2 weeks, maximum of 8 cycles)
Number of subjects: 517
Study 25332322 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck adipose tissue (NAT) compartments measurement
Number of subjects: 303
Study 25332322 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT compartments in women
Number of subjects: 303
Study 25332322 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT compartments in men
Number of subjects: 303
Study 25332322 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of NAT across lean, overweight, and obese groups
Number of subjects: 303
Study 25332326 — intervention group
Group type: EXPERIMENTAL
Intervention: [(13)C5]5-formyltetrahydrofolate delivered in a pH-sensitive enteric caplet (855 nmol / 400 μg)
Number of subjects: 0
Study 25332326 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of [(13)C5]5-formyltetrahydrofolate (214 nmol)
Number of subjects: 0
Study 25332483 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 g/d LNS with milk protein base (milk-LNS)
Number of subjects: 840
Study 25332483 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 g/d LNS with soy protein base (soy-LNS)
Number of subjects: 840
Study 25332483 — intervention group
Group type: EXPERIMENTAL
Intervention: 71 g/d corn-soy blend (CSB)
Number of subjects: 840
Study 25332483 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 840
Study 25332483 — intervention group
Group type: EXPERIMENTAL
Intervention: milk-LNS
Number of subjects: 840
Study 25332483 — intervention group
Group type: EXPERIMENTAL
Intervention: soy-LNS
Number of subjects: 840
Study 25332483 — intervention group
Group type: EXPERIMENTAL
Intervention: CSB
Number of subjects: 840
Study 25332483 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (milk-LNS, soy-LNS, CSB, Control)
Number of subjects: 840
Study 25333474 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-weighted STIR
Number of subjects: 40
Study 25333474 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 mapping
Number of subjects: 40
Study 25333474 — intervention group
Group type: EXPERIMENTAL
Intervention: ACUT2E
Number of subjects: 40
Study 25333474 — intervention group
Group type: EXPERIMENTAL
Intervention: EGE
Number of subjects: 40
Study 25334031 — intervention group
Group type: EXPERIMENTAL
Intervention: ClinicalTrials.gov registry
Number of subjects: 437
Study 25334031 — intervention group
Group type: COMPARATOR
Intervention: Contacting trial coordinators
Number of subjects: 437
Study 25335783 — intervention group
Group type: EXPERIMENTAL
Intervention: pMTCT cascade analysis tool
Number of subjects: 32
Study 25335932 — intervention group
Group type: EXPERIMENTAL
Intervention: OSI-906 50 mg BID; everolimus 5 mg QD
Number of subjects: 18
Study 25335932 — intervention group
Group type: EXPERIMENTAL
Intervention: OSI-906 100 mg BID; everolimus 10 mg QD
Number of subjects: 18
Study 25335932 — intervention group
Group type: EXPERIMENTAL
Intervention: OSI-906 100 mg BID; everolimus 5 mg QD
Number of subjects: 18
Study 25336464 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg IV infusion at baseline and on day 15)
Number of subjects: 20
Study 25336940 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1
Number of subjects: 153
Study 25336940 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MWD
Number of subjects: 153
Study 25336940 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 153
Study 25336940 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect effect of FEV1 on 6MWD through IL-6
Number of subjects: 153
Study 25336940 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a moderator
Number of subjects: 153
Study 25338281 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2 imaging
Number of subjects: 44
Study 25338281 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-MDP bone scan
Number of subjects: 44
Study 25338318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (oral, small-molecule tyrosine kinase inhibitor)
Number of subjects: 36
Study 25338926 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG ≥5.6 mmol/L
Number of subjects: 216
Study 25338926 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C ≥ 5.7% (39 mmol/mol)
Number of subjects: 216